Specializing in the Registration, Supply Chain and Commercialization of RLDs (Reference Listed Drugs)
A professional, compliant and efficient academic promotion system.
A good, smooth and effective communication mechanism..
High-quality investigation reports. A Highly qualified team with rich experiences.
Flexible provision of services in various forms.
This product is suitable for postmenopausal osteoporosis; Chronic renal failure, especially renal osteodystrophy in patients undergoing hemodialysis; Postoperative hypothyroidism; Idiopathic hypoparathyroidism;
Hesenna promotes the implementation of the osteoporosis integrated diagnosis and treatment scheme.
Hesenna focuses on the prevention and treatment of SREs in patients with tumor bone metastasis.
Hesenna has already made inroads into the rare disease domain. We will focus on promoting the development of diagnosis and treatment for narcolepsy, providing effective medication for and benefiting more narcolepsy patients.
Osteoporosis is one of the serious social problems faced by the aging society. However, there are still many misunderstandings and gaps in the public’s understanding of it. On March 23, the “China’s osteoporosis experts’ opinions” science popularization project free clinic event was held simultaneously…
Narcolepsy is a globally recognized rare disease. In Asia, the prevalence rate of this condition is 0.0129% in Taiwan and 0.015% in South Korea. The peak age of onset in China is 8-12 years old. Currently, narcolepsy faces challenges such as low public awareness…
Based in China and facing the world, HSN is a pharmaceutical group that provides integrated services of Commercialization, supply chain, and brand promotion of foreign high-end patented drugs in China. An emerging strategic partner for your brand.
Copyright © 2024 – Hesenna Medicine All rights reserved.
